BioSpace News Archive

Haematologic Technologies, a global analytical and bioanalytical leader for large molecule drug development, announced they’ll be operating under the new name, Prolytix — integrating HT and Haemtech Biopharma Services.

Modulus Discovery, Inc., a preclinical-stage computation-driven drug discovery firm, announces the successful closing of its Series C funding round in the amount of 2.34B JPY.

Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced the presentation of an e-Poster at the 2022 European Society for Medical Oncology (ESMO) Targeted Anticancer Therapies Congress, which is being held virtually from March 7 – 8, 2022.

FineHeart S.A, a preclinical medical device company that has developed the ICOMS FLOWMAKER®, a fully Implantable Cardiac Output Management System designed to address the unmet need of patients suffering from severe heart failure, today announced the grant by the USPTO (United States Patent and Trademark Office) in the United States, of their new patent US 11 097093.

CinCor Pharma, Inc. today announced that its management team will present at the 32 nd Annual Oppenheimer Healthcare Conference taking place March 15-17, 2022.

Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and a strong emerging pipeline, today announced that the U.S. Food and Drug Administration, or FDA, has granted orphan-drug designation for INBRX-101 for the treatment of alpha-1 antitrypsin deficiency, or AATD.

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the Cowen 42nd Annual Health Care Conference on Wednesday, March 9, 2022 at 2:50 p.m. Eastern Time.

MemorialCare Heart & Vascular Institute (MHVI), through its advanced research program, is participating in a CSL Behring-sponsored multi-center, Phase III clinical trial – “ApoA-I Event reducinG in Ischemic Syndromes II (AEGIS-II) – which is studying the removal of cholesterol from the arteries to reduce the risk of a second heart attack or stroke in patients.

Canopy Biosciences, a Bruker Company, today announced the commercial launch of the CellScapeTM system, the next generation in ChipCytometryTM instrumentation, advancing the cutting-edge for quantitative in situ spatial phenotyping.

Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage company developing precision oncology therapeutics, today reports financial results for the fourth quarter and full year ended December 31, 2021, along with an update on the Company’s key developments, business operations and upcoming milestones.